Gene-expression profiling elucidates molecular signaling networks that can be therapeutically targeted in vestibular schwannoma
- PMID: 25245477
- DOI: 10.3171/2014.6.JNS131433
Gene-expression profiling elucidates molecular signaling networks that can be therapeutically targeted in vestibular schwannoma
Abstract
Object: Vestibular schwannomas (VS) are common benign tumors of the vestibular nerve that cause significant morbidity. The current treatment strategies for VS include surgery or radiation, with each treatment option having associated complications and side effects. The transcriptional landscape of schwannoma remains largely unknown.
Methods: In this study the authors performed gene-expression profiling of 49 schwannomas and 7 normal control vestibular nerves to identify tumor-specific gene-expression patterns. They also interrogated whether schwannomas comprise several molecular subtypes using several transcription-based clustering strategies. The authors also performed in vitro experiments testing therapeutic inhibitors of over-activated pathways in a schwannoma cell line, namely the PI3K/AKT/mTOR pathway.
Results: The authors identified over 4000 differentially expressed genes between controls and schwannomas with network analysis, uncovering proliferation and anti-apoptotic pathways previously not implicated in VS. Furthermore, using several distinct clustering technologies, they could not reproducibly identify distinct VS subtypes or significant differences between sporadic and germline NF2-associated schwannomas, suggesting that they are highly similar entities. The authors identified overexpression of PI3K/AKT/mTOR signaling networks in their gene-expression study and evaluated this pathway for therapeutic targeting. Testing the compounds BEZ235 and PKI-587, both novel dual inhibitors of PI3K and mTOR, attenuated tumor growth in a preclinical cell line model of schwannoma (HEI-293). In vitro findings demonstrated that pharmacological inhibition of the PI3K/AKT/mTOR pathway with next-generation compounds led to decreased cell viability and increased cell death.
Conclusions: These findings implicate aberrant activation of the PI3K/AKT/mTOR pathway as a molecular mechanism of pathogenesis in VS and suggest inhibition of this pathway as a potential treatment strategy.
Keywords: ERM = ezrin, moesin, and radixin; MAD = median absolute deviation; NF2 = neurofibromatosis Type 2; NMF = nonnegative matrix factorization; PCA = principal component analysis; PDGF = platelet-derived growth factor; PDGFR = PDGF receptor; PI3K-AKT inhibitors; ROS = reactive oxygen species; VS = vestibular schwannoma; c-KIT = stem cell factor receptor; miRNA = micro-RNA; molecular profiling; therapeutics; vestibular schwannoma.
Comment in
-
Therapeutic targeting based on gene-expression profiling in vestibular schwannomas.J Neurosurg. 2014 Dec;121(6):1432-3. doi: 10.3171/2014.2.JNS14321. Epub 2014 Sep 23. J Neurosurg. 2014. PMID: 25245342 No abstract available.
-
Response.J Neurosurg. 2014 Dec;121(6):1433. J Neurosurg. 2014. PMID: 25584369 No abstract available.
Similar articles
-
Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.Cell Biochem Funct. 2013 Jul;31(5):427-33. doi: 10.1002/cbf.2917. Epub 2012 Oct 22. Cell Biochem Funct. 2013. PMID: 23086777
-
Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.BMC Cancer. 2019 Jun 24;19(1):618. doi: 10.1186/s12885-019-5824-9. BMC Cancer. 2019. PMID: 31234823 Free PMC article.
-
Targeting of PI3K/AKT/mTOR pathway to inhibit T cell activation and prevent graft-versus-host disease development.J Hematol Oncol. 2016 Oct 20;9(1):113. doi: 10.1186/s13045-016-0343-5. J Hematol Oncol. 2016. PMID: 27765055 Free PMC article.
-
Molecular pathogenesis of vestibular schwannomas: insights for the development of novel medical therapies.Otolaryngol Pol. 2012 Mar-Apr;66(2):84-95. doi: 10.1016/S0030-6657(12)70754-0. Otolaryngol Pol. 2012. PMID: 22500497 Review.
-
The molecular biology and novel treatments of vestibular schwannomas.J Neurosurg. 2011 Nov;115(5):906-14. doi: 10.3171/2011.6.JNS11131. Epub 2011 Jul 29. J Neurosurg. 2011. PMID: 21800959 Review.
Cited by
-
Potential Molecular Biomarkers of Vestibular Schwannoma Growth: Progress and Prospects.Front Oncol. 2021 Sep 27;11:731441. doi: 10.3389/fonc.2021.731441. eCollection 2021. Front Oncol. 2021. PMID: 34646772 Free PMC article. Review.
-
Vascular hyperpermeability as a hallmark of phacomatoses: is the etiology angiogenesis related to or comparable with mechanisms seen in inflammatory pathways? Part II: angiogenesis- and inflammation-related molecular pathways, tumor-associated macrophages, and possible therapeutic implications: a comprehensive review.Neurosurg Rev. 2018 Oct;41(4):931-944. doi: 10.1007/s10143-017-0837-9. Epub 2017 Mar 11. Neurosurg Rev. 2018. PMID: 28283837 Review.
-
Current molecular understanding of central nervous system schwannomas.Acta Neuropathol Commun. 2025 Feb 5;13(1):24. doi: 10.1186/s40478-025-01937-w. Acta Neuropathol Commun. 2025. PMID: 39910685 Free PMC article. Review.
-
The Novel Small Molecule Inhibitor, OSU-T315, Suppresses Vestibular Schwannoma and Meningioma Growth by Inhibiting PDK2 Function in the AKT Pathway Activation.Austin J Med Oncol. 2016;3(1):1025. Epub 2016 Apr 21. Austin J Med Oncol. 2016. PMID: 27642646 Free PMC article.
-
Role of Merlin/NF2 inactivation in tumor biology.Oncogene. 2016 Feb 4;35(5):537-48. doi: 10.1038/onc.2015.125. Epub 2015 Apr 20. Oncogene. 2016. PMID: 25893302 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous